{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:10:03Z","timestamp":1759065003559,"version":"3.44.0"},"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.antiviral.2022.105447","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T23:13:56Z","timestamp":1665789236000},"page":"105447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antiviral Research: At age 41, a transition"],"prefix":"10.1016","volume":"208","author":[{"given":"Mike","family":"Bray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105447_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104805","article-title":"Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses","volume":"178","author":"Bray","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105447_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2022.105447_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2011.07.010","article-title":"Antiviral research, at its 30th anniversary, remembrances from its editor-in-chief","volume":"92","author":"De Clercq","year":"2011","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:36:11Z","timestamp":1759062971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222002169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":3,"alternative-id":["S0166354222002169"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105447","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Research: At age 41, a transition","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105447"}}